Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CEL | P19835 | 2/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.31 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | HTR2A | P28223 | 2/20 | 0.31 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | HTR2B | P41595 | 2/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17981532 | 0.81 | MEN1 (0.36) | ALDH1A1MEN1KMT2ATDP1CEL | |
| SCHEMBL319907 | 0.81 | MEN1 (0.59) | ALDH1A1MEN1KMT2ATDP1CEL | |
| SCHEMBL954689 | 0.77 | MEN1 (0.41) | ALDH1A1MEN1KMT2ATDP1GRIA1 | |
| SCHEMBL19671578 | 0.76 | ALDH1A1 (0.57) | ALDH1A1MEN1KMT2ATDP1CEL | |
| SCHEMBL189622 | 0.74 | ALDH1A1 (0.59) | ALDH1A1MEN1KMT2ATDP1HTR2A | |
| SCHEMBL30660275 | 0.71 | TDP1 (0.44) | ALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL18299302 | 0.70 | STS (0.33) | MEN1KMT2ASLC6A3 | |
| SCHEMBL321198 | 0.69 | ERN1 (0.37) | ALDH1A1MEN1KMT2ATDP1SLC6A3 | |
| SCHEMBL956784 | 0.69 | HTR2C (0.44) | ALDH1A1MEN1KMT2ATDP1HTR2C | |
| SCHEMBL24512766 | 0.69 | ALDH1A1 (0.55) | ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689369-B2 | Substituted indazole compounds as RORgammaT inhibitors and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190276438-A1 | SUBSTITUTED INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME LLC | 2019-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190276438-A1 | SUBSTITUTED INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | RORB, RORC, RORA | ALDH1A1 446/4885MEN1 2764/4885KMT2A 1551/4885 |
| US-10689369-B2 | Substituted indazole compounds as RORgammaT inhibitors and uses thereof | RORB, RORC, RORA | ALDH1A1 446/4885MEN1 2764/4885KMT2A 1551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.